Spondyloarthritis & psoriatic arthritis
Inadequate response to anti-TNFα therapy is associated with a gain-of-function TNFR2-R polymorphic variant in patients with psoriatic arthritis
Main finding · Discontinuation of TNFi therapy <12 monthsResult — go to the resultLikelihood of discontinuation ∼5-fold 95% CI 1.98–12.78Authors' conclusion
TNFR2 rs1061622 polymorphism significantly influences TNFi therapy responsiveness in PsA. The TNFα-independent, but ROCK activity-dependent gain-of-function activity conferred by TNFR2-R variant potentially serves as a mechanism underlying inadequate responses to TNFi in a subset of patients with PsA.
Study context
- Population
- Patients with psoriatic arthritis (PsA) treated with TNFi
- Participants
- 164 patients
- Comparison
- TNFR2-R vs TNFR2-M rs1061622 variant carriers
- Outcome
- Discontinuation of TNFi <12 months due to inadequate efficacy (chart review)
- Follow-up
- 12 months
Methodological detailsrestriction fragment length polymorphism analysis, chart review, in vitro cell studies
- Restriction fragment length polymorphism analysis
- Chart review
- In vitro cell studies
Main finding
Discontinuation of TNFi therapy <12 months
Likelihood of discontinuation
∼5-fold
95% CI 1.98–12.78
As reported in the abstract
Further findings
| Outcome | P value |
|---|---|
| Proinflammatory gene expression without TNFα stimulation (cells)Higher in cells with TNFR2-R alleles | P < 0.01 |
TNFR2-R activity under inhibition (cells)
- Unaffected by a TNFα-neutralising antibody; blocked by a ROCK-specific inhibitor
Original publication
Inadequate response to anti-TNFα therapy is associated with a gain-of-function TNFR2-R polymorphic variant in patients with psoriatic arthritis. Ann Rheum Dis. Published 7 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →